Skip to main content

Table 3 Treatment patterns by patient subgroup

From: Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer

Subgroup

n

Anti–PD-1/ PD-L1 monotherapy, n (%)

Atezolizumab, n (%)

Nivolumab, n (%)

Pembrolizumab, n (%)

Anti–PD-1/ PD-L1 therapy + platinum-based CT, n (%)

Pembrolizumab + platinum-based CT, n (%)

Anti–PD-1/ PD-L1 therapy + any therapy other than platinum-based CT, n (%)

Nivolumab + ipilimumab, n (%)

Age group

 <65 years

846

379 (44.8)

17 (4.5)

100 (26.4)

262 (69.1)

447 (52.8)

429 (96.0)

20 (2.4)

9 (45.0)

 65–74 years

759

361 (47.6)

18 (5.0)

87 (24.1)

256 (70.9)

357 (47.0)

344 (96.4)

41 (5.4)

22 (53.7)

 ≥75 years

570

363 (63.7)

23 (6.3)

84 (23.1)

256 (70.5)

185 (32.5)

177 (95.7)

22 (3.9)

16 (72.7)

Sex

 Male

1169

581 (49.7)

36 (6.2)

137 (23.6)

408 (70.2)

548 (46.9)

526 (96.0)

40 (3.4)

23 (57.5)

 Female

1006

522 (51.9)

22 (4.2)

134 (25.7)

366 (70.1)

441 (43.8)

424 (96.1)

43 (4.3)

24 (55.8)

Histology

 Nonsquamous

1447

691 (47.8)

31 (4.5)

154 (22.3)

506 (73.2)

705 (48.7)

686 (97.3)

51 (3.5)

25 (49.0)

 Squamous

457

267 (58.4)

19 (7.1)

84 (31.5)

164 (61.4)

168 (36.8)

164 (97.6)

22 (4.8)

18 (81.8)

Number of metastatic sites

 0

23

12 (52.2)

1 (8.3)

5 (41.7)

6 (50.0)

9 (39.1)

9 (100.0)

2 (8.7)

2 (100.0)

 1

1404

734 (52.3)

42 (5.7)

189 (25.7)

503 (68.5)

616 (43.9)

592 (96.1)

54 (3.8)

33 (61.1)

 2

504

243 (48.2)

9 (3.7)

46 (18.9)

188 (77.4)

238 (47.2)

230 (96.6)

23 (4.6)

11 (47.8)

 ≥3

173

73 (42.2)

1 (1.4)

19 (26.0)

53 (72.6)

97 (56.1)

91 (93.8)

3 (1.7)

0

NSCLC stage at index date

 3

78

42 (53.8)

4 (9.5)

12 (28.6)

26 (61.9)

33 (42.3)

32 (97.0)

3 (3.8)

2 (66.7)

 4

2097

1061 (50.6)

54 (5.1)

259 (24.4)

748 (70.5)

956 (45.6)

918 (96.0)

80 (3.8)

45 (56.3)

Brain metastases

 Yes

499

261 (52.3)

9 (3.4)

50 (19.2)

202 (77.4)

221 (44.3)

210 (95.0)

17 (3.4)

8 (47.1)

 No

1676

842 (50.2)

49 (5.8)

221 (26.2)

572 (67.9)

768 (45.8)

740 (96.4)

66 (3.9)

39 (59.1)

ECOG PS

 0 or 1

1408

653 (46.4)

26 (4.0)

152 (23.3)

475 (72.7)

698 (49.6)

670 (96.0)

57 (4.0)

35 (61.4)

 ≥2

430

242 (56.3)

8 (3.3)

61 (25.2)

173 (71.5)

171 (39.8)

163 (95.3)

17 (4.0)

7 (41.2)

Smoking status

 Current or former

1912

946 (49.5)

45 (4.8)

226 (23.9)

675 (71.4)

897 (46.9)

860 (95.9)

69 (3.6)

41 (59.4)

 Never

263

157 (59.7)

13 (8.3)

45 (28.7)

99 (63.1)

92 (35.0)

90 (97.8)

14 (5.3)

6 (42.9)

Patient immunocompromiseda, b

 Yes

240

126 (52.5)

9 (7.1)

37 (29.4)

80 (63.5)

95 (39.6)

86 (90.5)

19 (7.9)

11 (57.9)

History of autoimmune disease

 Yes

33

11 (33.3)

1 (9.1)

4 (36.4)

6 (54.5)

15 (45.5)

14 (93.3)

7 (21.2)

5 (71.4)

 No

2142

1092 (51.0)

57 (5.2)

267 (24.5)

768 (70.3)

974 (45.5)

936 (96.1)

76 (3.5)

42 (55.3)

Patients positive for RET, BRAF, or MET mutations

 Yes

179

94 (52.5)

1 (1.1)

20 (21.3)

73 (77.7)

77 (43.0)

75 (97.4)

8 (4.5)

4 (50.0)

PD-1/PD-L1 expressionc

 1–49%

62

27 (43.5)

5 (18.5)

10 (37.0)

12 (44.4)

35 (56.5)

35 (100.0)

0

0

 ≥50%

115

84 (73.0)

1 (1.2)

6 (7.1)

77 (91.7)

26 (22.6)

23 (88.5)

5 (4.3)

0

  1. BRAF proto-oncogene B-Raf, CT chemotherapy, ECOG PS Eastern Cooperative Oncology Group performance status, HIV human immunodeficiency virus, MET mesenchymal epithelial transition factor, NSCLC non-small cell lung cancer, PD-1 programmed cell death protein 1, PD-L1 programmed cell death ligand 1, RET RET proto-oncogene
  2. aImmunocompromised defined as having HIV or taking long-term (≥30 days) immunosuppressive medications
  3. bHaving HIV, long-term use of prednisone/prednisolone, and long-term use of other immunosuppressive medications are not mutually exclusive
  4. cAt the time of analysis, the completeness/availability of expression results in the Patient360 NSCLC database was limited
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us